{"id":47319,"date":"2022-08-16T12:01:41","date_gmt":"2022-08-16T10:01:41","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\/"},"modified":"2022-08-16T12:01:41","modified_gmt":"2022-08-16T10:01:41","slug":"evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\/","title":{"rendered":"Evonetix Commences Early Access Program for DNA Synthesised by Thermal Control on Its Semiconductor Chip"},"content":{"rendered":"
\n

\nResearchers are invited to apply<\/a> to receive DNA that has been synthesised using Evonetix\u2019s platform<\/i>\n<\/p>\n

CAMBRIDGE, England–(BUSINESS WIRE)–EVONETIX LTD (\u2018Evonetix\u2019), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the opening of its early access program for semiconductor synthesised DNA. Evonetix\u2019s DNA synthesis capability brings together patented semiconductor chip design and proprietary, thermally controlled synthesis chemistry, which will be integral to the Company\u2019s future gene synthesis platforms.\n<\/p>\n

<\/a><\/p>\n

\nEvonetix\u2019s proprietary process utilises a novel silicon chip to control the synthesis of DNA at many thousands of independent thermally controlled reaction sites, or \u2018pixels\u2019, on the chip surface. Combined with the Company\u2019s patented chemistry, this approach enables the accurate synthesis of thousands of sequences on a single chip to meet the demand for complex libraries and assembly of long DNA, addressing the DNA supply bottleneck in the field of synthetic biology.\n<\/p>\n

\nResearchers are invited to apply to be included in the Company\u2019s early access program to receive some of the first DNA prepared using its technology and demonstrate the efficacy of Evonetix DNA in routine molecular biology workflows. The Company will then look to scale up the parallel synthesis capacity of its semiconductor chips as it works toward future full commercialisation of its technology.\n<\/p>\n

\nMatt Hayes, Founder and Chief Technology Officer at Evonetix, said: <\/b>\u201cWe have been working on optimising the different elements of our technology ready to share DNA with researchers. Reaching this point in our development is a key milestone, paving the way for the expansion in scale that only semiconductor-based technologies can achieve.\u201d<\/i>\n<\/p>\n

\nColin McCracken, CEO of Evonetix added:<\/b> \u201cBiology is driving a revolution that will change the way we live and help solve some of the biggest problems faced by our planet today. At the core of this is the ability to deliver DNA better and faster to researchers working on these global challenges. The current model for DNA synthesis can\u2019t deliver on the future demand for DNA. Building a platform capable of this requires highly parallel, distributed synthesis. Evonetix is ready to meet these challenges and open the door to the exciting next phase of our development.\u201d<\/i>\n<\/p>\n

\nTo apply to be included in the early access program, please visit: www.evonetix.com\/access<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nLorna Cuddon
\n
Zyme Communications
\n
lorna.cuddon@zymecommunications.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Researchers are invited to apply to receive DNA that has been synthesised using Evonetix\u2019s platform CAMBRIDGE, England–(BUSINESS WIRE)–EVONETIX LTD (\u2018Evonetix\u2019), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the opening of its early access program for semiconductor synthesised DNA. Evonetix\u2019s DNA synthesis capability brings together patented semiconductor chip design and proprietary, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47319","6":"format-standard","7":"category-industry"},"yoast_head":"\nEvonetix Commences Early Access Program for DNA Synthesised by Thermal Control on Its Semiconductor Chip - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evonetix Commences Early Access Program for DNA Synthesised by Thermal Control on Its Semiconductor Chip - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Researchers are invited to apply to receive DNA that has been synthesised using Evonetix\u2019s platform CAMBRIDGE, England–(BUSINESS WIRE)–EVONETIX LTD (\u2018Evonetix\u2019), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the opening of its early access program for semiconductor synthesised DNA. Evonetix\u2019s DNA synthesis capability brings together patented semiconductor chip design and proprietary, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-16T10:01:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220816005493\/en\/1545334\/21\/Evonetix_Ltd.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Evonetix Commences Early Access Program for DNA Synthesised by Thermal Control on Its Semiconductor Chip\",\"datePublished\":\"2022-08-16T10:01:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\\\/\"},\"wordCount\":402,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220816005493\\\/en\\\/1545334\\\/21\\\/Evonetix_Ltd.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\\\/\",\"name\":\"Evonetix Commences Early Access Program for DNA Synthesised by Thermal Control on Its Semiconductor Chip - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220816005493\\\/en\\\/1545334\\\/21\\\/Evonetix_Ltd.jpg\",\"datePublished\":\"2022-08-16T10:01:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220816005493\\\/en\\\/1545334\\\/21\\\/Evonetix_Ltd.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220816005493\\\/en\\\/1545334\\\/21\\\/Evonetix_Ltd.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evonetix Commences Early Access Program for DNA Synthesised by Thermal Control on Its Semiconductor Chip\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evonetix Commences Early Access Program for DNA Synthesised by Thermal Control on Its Semiconductor Chip - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\/","og_locale":"en_US","og_type":"article","og_title":"Evonetix Commences Early Access Program for DNA Synthesised by Thermal Control on Its Semiconductor Chip - Pharma Trend","og_description":"Researchers are invited to apply to receive DNA that has been synthesised using Evonetix\u2019s platform CAMBRIDGE, England–(BUSINESS WIRE)–EVONETIX LTD (\u2018Evonetix\u2019), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the opening of its early access program for semiconductor synthesised DNA. Evonetix\u2019s DNA synthesis capability brings together patented semiconductor chip design and proprietary, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-16T10:01:41+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220816005493\/en\/1545334\/21\/Evonetix_Ltd.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Evonetix Commences Early Access Program for DNA Synthesised by Thermal Control on Its Semiconductor Chip","datePublished":"2022-08-16T10:01:41+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\/"},"wordCount":402,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220816005493\/en\/1545334\/21\/Evonetix_Ltd.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\/","url":"https:\/\/pharma-trend.com\/en\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\/","name":"Evonetix Commences Early Access Program for DNA Synthesised by Thermal Control on Its Semiconductor Chip - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220816005493\/en\/1545334\/21\/Evonetix_Ltd.jpg","datePublished":"2022-08-16T10:01:41+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220816005493\/en\/1545334\/21\/Evonetix_Ltd.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220816005493\/en\/1545334\/21\/Evonetix_Ltd.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/evonetix-commences-early-access-program-for-dna-synthesised-by-thermal-control-on-its-semiconductor-chip\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Evonetix Commences Early Access Program for DNA Synthesised by Thermal Control on Its Semiconductor Chip"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47319"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47319\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}